Pemigatinib in the Real-World Management of Cholangiocarcinoma Through a Canadian Patient Support Program

Pemigatinib in the Real-World Management of Cholangiocarcinoma Through a Canadian Patient Support Program

Background: In September 2021, pemigatinib received Health Canada approval for previously treated locally advanced/metastatic cholangiocarcinoma (CCA) with <i>FGFR2</i> rearrangements/fusions. This retrospective study aimed to characterize the real-world management and outcomes of patien...

Full description

Saved in:
Bibliographic Details
Main Authors: Philip Q. Ding, Vincent C. Tam, Ravi Ramjeesingh, Jamil Asselah, Brandon S. Sheffield, Taylor Mitchell, Anne-Julie Gaudreau, Jennifer J. Knox, Winson Y. Cheung
Format: Article
Language:English
Published: MDPI AG 2025-07-01
Series:Current Oncology
Subjects:
cholangiocarcinoma
real world
pemigatinib
systemic therapy
response
survival
Online Access:https://www.mdpi.com/1718-7729/32/7/405
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1718-7729/32/7/405

Similar Items